Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Invested Capital: 2010-2021

Historic Invested Capital for Neurocrine Biosciences (NBIX) over the last 11 years, with Sep 2021 value amounting to $1.3 billion.

  • Neurocrine Biosciences' Invested Capital rose 9.49% to $1.3 billion in Q3 2021 from the same period last year, while for Sep 2021 it was $1.3 billion, marking a year-over-year increase of 9.49%. This contributed to the annual value of $1.1 billion for FY2020, which is 2.44% down from last year.
  • According to the latest figures from Q3 2021, Neurocrine Biosciences' Invested Capital is $1.3 billion, which was up 5.22% from $1.3 billion recorded in Q2 2021.
  • In the past 5 years, Neurocrine Biosciences' Invested Capital ranged from a high of $1.3 billion in Q3 2021 and a low of $247.9 million during Q1 2017.
  • For the 3-year period, Neurocrine Biosciences' Invested Capital averaged around $1.2 billion, with its median value being $1.2 billion (2021).
  • As far as peak fluctuations go, Neurocrine Biosciences' Invested Capital crashed by 40.11% in 2017, and later skyrocketed by 255.74% in 2018.
  • Over the past 5 years, Neurocrine Biosciences' Invested Capital (Quarterly) stood at $889.6 million in 2017, then rose by 12.21% to $998.3 million in 2018, then rose by 15.64% to $1.2 billion in 2019, then dropped by 2.44% to $1.1 billion in 2020, then rose by 9.49% to $1.3 billion in 2021.
  • Its last three reported values are $1.3 billion in Q3 2021, $1.3 billion for Q2 2021, and $1.2 billion during Q1 2021.